Date:2/28/2011

orical facts, included in this press release regarding Nile's plans to develop cenderitide in the post-acute setting, the anticipated benefits of cenderitide for patients in the post-acute setting, and Nile's plans to seek Fast Track designation of Cenderitide and initiate clinical trials in the post-acute setting, are forward-looking statements.  Forward-looking statements also include statements regarding the timing, progress and anticipated results of the clinical development, regulatory processes, clinical trial timelines, expected patient enrollment, anticipated benefits of cenderitide, Nile's strategy, future operations, outlook, milestones, the timing and success of Nile's product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. Nile may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on Nile's forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Nile makes. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that Nile makes include Nile's need to raise additional capital to fund its product development programs to completion, Nile's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in greater detail in the reports Nile files with Securities and Exchange Commission, including those described under the caption "Risk Factors" in Item 1A of its Annual Report on Form 10-K for the year ended December 31, 2009 filed with the Securities and Exchange Commission on March 3, 2010. Nile is providing this information as of the date of this press release and does not undertake any obligation to updat
'/>"/>

SOURCE Nile Therapeutics, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Nile Therapeutics to Collaborate with Medtronic on Clinical Development of Cenderitide for Heart Failure and Renal Disease
2. Deston Therapeutics Stands By Safety and Efficacy of Auralgan After FDA Action
3. Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials
4. Cornerstone Therapeutics to Host Fourth Quarter and Full Year 2010 Conference Call
5. Echo Therapeutics Reports Symphony™ tCGM System Ahead of Schedule
6. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
7. Prime Therapeutics Vice President of Specialty Pharmacy Solutions Speaks at 16th Annual PBMI Drug Benefit Conference
8. Echo Therapeutics Announces Appointments to Board of Directors
9. Tarsa Therapeutics Completes Phase III Trial of its Oral Calcitonin for Treatment of Postmenopausal Osteoporosis and Initiates Phase II Trial in Osteoporosis Prevention
10. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End 2010 Financial Results on February 16
11. Cephalon Signs Option Agreement to Acquire Assets from Alba Therapeutics